Allied Corp. (ALID) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAllied Corp. (ALID) trades at $0.0005. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for ALID: ALID does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Allied Corp. (ALID) Healthcare & Pipeline Overview
Allied Corp. specializes in the research and production of cannabinoid health solutions, offering a range of hemp-derived products while navigating the evolving landscape of the medical cannabis industry.
What Is the Investment Thesis for ALID?
Allied Corp. presents a unique investment thesis driven by its innovative product portfolio and strategic focus on cannabinoid health solutions. With a market cap currently at $0.00B and a profit margin of -14807.6%, the company is in a critical phase of development, particularly with its ALID 10 and ALID 11 products targeting PTSD, which could tap into a significant and underserved market. The U.S. medical cannabis market is projected to grow substantially, driven by increasing acceptance and regulatory changes. As the company continues to refine its product offerings and expand its distribution channels, it is poised to capture a larger share of this expanding market. However, investors should remain cognizant of the inherent risks associated with the cannabis industry, including regulatory challenges and market volatility. Monitoring these factors will be essential to assess the company's ability to achieve its growth objectives and improve financial performance.
Based on FMP financials and quantitative analysis
ALID Key Highlights
Market cap currently at $0.00B reflects early-stage development in the cannabis industry.
- Profit margin of -14807.6% indicates significant investment in growth and product development.
- Gross margin of -2027.5% highlights the challenges in scaling operations and achieving profitability.
- Diverse product portfolio includes CBD tinctures, gummies, and topical applications targeting various health needs.
- Ongoing Phase I clinical trials for ALID 10 and ALID 11 represent potential future revenue streams.
Who Are ALID's Competitors?
ALID is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CRON Cronos Group Inc. | $3.31 | -1.19% | $1.22B | 92 5-pillar |
| TLRY Tilray Brands, Inc. | $2.72 | -3.20% | $314M | — |
| CGC Canopy Growth Corporation | $0.67 | -1.14% | $286M | — |
| APHA APHA | $15.27 | -1.04% | — | |
| IMCC IM Cannabis Corp. | $0.87 | -0.91% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.12 | +0.90% | $5.36M | — |
| SBFM Sunshine Biopharma, Inc. | $2.65 | -11.67% | $6.37M | — |
| BFRI Biofrontera Inc. | $0.82 | +4.17% | $11.7M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALID's Key Strengths?
Innovative product offerings tailored to consumer health needs.
- Strong focus on research and development for new therapeutic solutions.
- Established presence in the growing medical cannabis market.
- Diverse product portfolio enhancing market reach.
What Are ALID's Weaknesses?
Negative profit margins indicating financial challenges.
- Limited brand recognition compared to larger competitors.
- Dependence on regulatory approval for pharmaceutical products.
- Potential liquidity issues as an OTC listed company.
What Are the Key Risks for ALID?
Financial-distress signal — its Altman Z-Score of -48.13 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory changes that could affect product approval and market access.
- Competition from established players in the cannabis industry impacting market share.
- Economic downturns that may reduce consumer spending on wellness products.
- Market volatility leading to fluctuations in stock price and investor sentiment.
What Are ALID's Competitive Advantages?
- Innovative product development focused on cannabinoid health solutions.
- Established brand presence in the evolving cannabis market.
- Strong commitment to research and clinical trials for product efficacy.
- Diverse product portfolio catering to various consumer needs.
- Ability to adapt to regulatory changes in the cannabis industry.
What Does ALID Do?
Founded in 2013 and headquartered in Kelowna, Canada, Allied Corp. is a medical cannabis production company that engages in the research, development, and production of cannabinoid health solutions primarily in the United States. The company has evolved to offer a wide array of hemp-derived natural health products designed for various therapeutic applications. Among its flagship offerings are Liberty, a hemp-derived cannabidiol (CBD) tincture, and Tactical Hydration, a CBD-infused electrolyte replacement drink, which cater to health-conscious consumers. Allied Corp. also produces innovative products such as FIZZ Tablets, Battle Balm, and Quick Hit gummies under the Tactical Relief brand. Additionally, its Equilibrium Bio brand features Hydrosport CBD Drink and tinctures, while the MaXXa brand includes skincare products like Skin Structure and Eye Recover. Currently, Allied Corp. is advancing its pharmaceutical pipeline with ALID 10 and ALID 11, which are in Phase I clinical trials aimed at treating post-traumatic stress disorder (PTSD). This diversification into pharmaceuticals highlights the company's commitment to expanding its market presence and addressing unmet medical needs. As the cannabis industry continues to grow, Allied Corp. positions itself as a key player with a focus on innovation and quality in the rapidly evolving landscape of cannabinoid-based health solutions.
What Products and Services Does ALID Offer?
- Research, develop, and produce cannabinoid health solutions.
- Offer a variety of hemp-derived natural health products.
- Provide CBD-infused drinks, tinctures, and topical applications.
- Develop pharmaceutical products targeting specific health conditions.
- Focus on innovation and quality in product offerings.
- Engage in clinical trials for new therapeutic solutions.
How Does ALID Make Money?
- Generate revenue through the sale of hemp-derived health products.
- Develop pharmaceutical products for specific medical conditions.
- Leverage research and development to create innovative product lines.
- Expand distribution channels to reach a wider consumer base.
- Engage in partnerships to enhance product credibility and market presence.
What Industry Does ALID Operate In?
The cannabis industry, particularly the medical segment, is experiencing rapid growth, driven by increasing legalization and acceptance of cannabis products across various jurisdictions. Allied Corp. operates within this dynamic environment, competing against established players and new entrants in the specialty and generic drug manufacturing sector. The company's focus on cannabinoid health solutions positions it well to capitalize on the growing demand for natural health products and innovative therapies in the healthcare industry.
Who Are ALID's Key Customers?
- Health-conscious consumers seeking natural health products.
- Individuals with specific health conditions looking for cannabinoid solutions.
- Retailers and distributors of wellness products.
- Healthcare professionals recommending cannabinoid therapies.
- Patients participating in clinical trials for new products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Allied Corp. operates in the Healthcare sector. It is headquartered in Kelowna, CA. ALID has traded publicly since 2019.
Key Financial Metrics
Return on equity for Allied Corp. stands at 261.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Allied Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -48.13 places it in the distress zone, a signal of elevated financial risk.
Insider Activity
2 transactions · 2 purchases, 0 sales, 0 other transactions · 1 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
ALID Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
ALID Latest News
No recent news available for ALID.
ALID Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ALID.
Price Targets
Wall Street price target analysis for ALID.
ALID MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ALID; grades run from A+ (80-100) to F (below 30).
Leadership: Paul Bullock
CEO
Paul Bullock has extensive experience in the cannabis industry and has been instrumental in guiding Allied Corp. since its inception in 2013. With a strong background in business management and strategic development, he has led the company through various phases of growth and product innovation. His leadership is characterized by a commitment to research and development, particularly in cannabinoid health solutions.
Track Record: Under Paul Bullock's leadership, Allied Corp. has developed a diverse product portfolio and initiated clinical trials for innovative pharmaceutical products. His strategic vision has positioned the company to capitalize on emerging opportunities in the medical cannabis market.
ALID OTC Market Information
The OTC Other tier indicates that Allied Corp. is not listed on major exchanges like NYSE or NASDAQ, which typically have stricter reporting requirements and higher visibility. Companies in this tier may have less liquidity and fewer resources for investor communication.
- OTC Tier: OTC Other
- Limited liquidity may hinder the ability to buy or sell shares without impacting the stock price.
- Less stringent reporting requirements can lead to less transparency for investors.
- Regulatory risks associated with the cannabis industry can affect business operations and market perception.
- Market volatility can lead to significant price fluctuations.
- Verify the company's financial health through available reports.
- Assess the management team's experience and track record.
- Monitor regulatory developments in the cannabis industry.
- Evaluate the competitive landscape and market positioning.
- Review product offerings and pipeline developments.
- Established brand presence in the cannabis industry.
- Ongoing clinical trials for pharmaceutical products indicating commitment to research.
- Partnerships or collaborations with reputable organizations in the healthcare sector.
ALID Healthcare Stock FAQ
What are the main risks for ALID?
Allied Corp. faces several risks inherent to the cannabis industry, including regulatory changes that could impact product approvals and market access.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial metrics are subject to change and should be verified through official reports.